Study of Clinical Efficacy Information in Professional Labeling and Direct-to-Consumer (DTC) Print Advertisements for Prescription Drugs

ICR 201103-0910-005

OMB: 0910-0692

Federal Form Document

Forms and Documents
Document
Name
Status
Supplementary Document
2011-08-12
Supporting Statement B
2011-08-12
Supporting Statement A
2011-08-12
ICR Details
0910-0692 201103-0910-005
Historical Active
HHS/FDA
Study of Clinical Efficacy Information in Professional Labeling and Direct-to-Consumer (DTC) Print Advertisements for Prescription Drugs
New collection (Request for a new OMB Control Number)   No
Regular
Approved with change 08/12/2011
Retrieve Notice of Action (NOA) 03/20/2011
  Inventory as of this Action Requested Previously Approved
08/31/2014 36 Months From Approved
15,512 0 0
1,099 0 0
0 0 0

FDA regulations require that an advertisement that makes claims about a prescription drug include a "fair balance" of information about the benefits and risks of the advertised product, in terms of both content and presentation (21 CFR 202.1(e)(5)(ii)). In past research FDA has focused primarily on the risk component of the risk-benefit ratio. In the interest of thoroughly exploring the issue of fair balance, however, the presentation of effectiveness, or benefit, information is equally important.

US Code: 42 USC 300u(a)(4) Name of Law: Public health service Act
  
None

Not associated with rulemaking

  75 FR 34142 06/16/2010
75 FR 75477 12/03/2010
No

6
IC Title Form No. Form Name
Pretest, Physicians
Qestionaire, Physicians
Screener, Physicians
screener, consumers
Pretest consumers
Questionaire, consumers

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 15,512 0 0 15,512 0 0
Annual Time Burden (Hours) 1,099 0 0 1,099 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
Yes
Miscellaneous Actions
No
New collection

$378,100
Yes Part B of Supporting Statement
No
No
No
No
Uncollected
Eliazabeth Berbakos 3018271482

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
03/20/2011


© 2024 OMB.report | Privacy Policy